RVMD Latest Headlines

Daraxonrasib Poised to Become Pancreatic Cancer Standard of Care on Strong RASolute 302 Outlook and Accelerated Launch Path

at www.tipranks.com (Wed, 11-Mar 6:36 AM)

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP)

at www.tipranks.com (Tue, 10-Mar 9:50 PM)

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

at www.tipranks.com (Mon, 9-Mar 9:21 AM)

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (HIMS), ARS Pharmaceuticals (SPRY) and Revolution Medicines (RVMD)

at www.tipranks.com (Mon, 9-Mar 8:10 AM)

FDA Breakthrough Therapy Nod for Zoldonrasib Marks Major Milestone for Revolution Medicines

Market Chameleon (Fri, 9-Jan 10:35 AM)

FDA Grants Breakthrough Therapy Status to Revolution Medicines’ Zoldonrasib for Rare KRAS G12D Lung Cancer

Market Chameleon (Thu, 8-Jan 8:14 AM)